Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Amgen and its partners at Novartis are one step closer to fielding a new migraine drug in the US. The pharma giants said Thursday afternoon that the FDA has accepted their application for erenumab, the furthest advanced CGRP therapy which is now navigating toward a May 17 PDUFA date.
The companies have now dubbed the drug Aimovig, with pivotal data from 2,600 patients.
This is likely going to be quite a crowded field, though, with a lineup of developers positioning their own late-stage products for the last leg of the race through the agency. And the data so far indicate that several of these new drugs will look a lot alike.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.